ASH 2016 | Re-analysis of RESONATE-2 trial of ibrutinib vs chlorambucil in CLL
Paolo Ghia, MD, PhD of Università Vita-Salute San Raffaele, Milan, Italy, discusses the re-analysis of the RESONATE-2 trial comparing chlorambucil vs ibrutinib as first-line treatment for elderly chronic lymphocytic leukemia (CLL) patients with co-morbidities (NCT01722487). The update shows the data is still consistent with the original results; ibrutinib shows high efficacy and this translates in overall survival (OS). Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
Get great new content delivered to your inboxSign up